Announcements Trials
Browse Landscape

Status

Withdrawn 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

Injections 39Carboplatin 33Capecitabine 24Paclitaxel 23Cisplatin 23Docetaxel 22pembrolizumab 21Oxaliplatin 21Gemcitabine 21Bevacizumab 19Pemetrexed 18Fluorouracil 13Irinotecan 12Cyclophosphamide 11osimertinib 9Nivolumab 9Dexamethasone 8Topotecan 7Leucovorin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6tislelizumab 6regorafenib 6lenvatinib 6fludarabine 6Doxorubicin 6Cetuximab 6daratumumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × relmacabtagene autoleucel × Clear all
NCT06142188 2023-11-21

Relmacabtagene Autoleucel in Hematologic Malignancies

Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡